Schedule 13D ownership disclosure

AQUINOX PHARMACEUTICALS, INC

Security class unavailable · CUSIP: 03842B101

Event date: 2016-03-15

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
7,752,487
Percent of class
45.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001144204-16-088527
Form type
SC 13D/A
Filer
Neurogene Inc.
CIK
CIK 1404644
Filed
Mar 16, 2016
Reporting period
Mar 15, 2016
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub